Genethera Stock Buy Hold or Sell Recommendation
| GTHR Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding GeneThera is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell GeneThera given historical horizon and risk tolerance towards GeneThera. When Macroaxis issues a 'buy' or 'sell' recommendation for GeneThera, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out GeneThera Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as GeneThera and provide practical buy, sell, or hold advice based on investors' constraints. GeneThera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
GeneThera |
Execute GeneThera Buy or Sell Advice
The GeneThera recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on GeneThera. Macroaxis does not own or have any residual interests in GeneThera or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute GeneThera's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
GeneThera Trading Alerts and Improvement Suggestions
| GeneThera generated a negative expected return over the last 90 days | |
| GeneThera has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (1.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GeneThera currently holds about 140.1 K in cash with (8.57 K) of positive cash flow from operations. | |
| Roughly 18.0% of the company shares are held by company insiders |
GeneThera Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to GeneThera or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that GeneThera's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a GeneThera pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
GeneThera Volatility Alert
At this time GeneThera exhibits very low volatility. GeneThera appears to be a penny stock. Although GeneThera may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in GeneThera or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on GeneThera instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.GeneThera Fundamentals Vs Peers
Comparing GeneThera's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze GeneThera's direct or indirect competition across all of the common fundamentals between GeneThera and the related equities. This way, we can detect undervalued stocks with similar characteristics as GeneThera or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of GeneThera's fundamental indicators could also be used in its relative valuation, which is a method of valuing GeneThera by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare GeneThera to competition |
| Fundamentals | GeneThera | Peer Average |
| Return On Asset | -95.38 | -0.14 |
| Current Valuation | 1.44 M | 16.62 B |
| Shares Outstanding | 35.33 M | 571.82 M |
| Shares Owned By Insiders | 17.99 % | 10.09 % |
| Price To Earning | (0.17) X | 28.72 X |
| EBITDA | (1 M) | 3.9 B |
| Net Income | (1.01 M) | 570.98 M |
| Cash And Equivalents | 140.1 K | 2.7 B |
| Total Debt | 806.87 K | 5.32 B |
| Book Value Per Share | (0.24) X | 1.93 K |
| Cash Flow From Operations | (8.57 K) | 971.22 M |
| Earnings Per Share | (0.03) X | 3.12 X |
| Number Of Employees | 2 | 18.84 K |
| Beta | 0.89 | -0.15 |
| Market Capitalization | 533.53 K | 19.03 B |
| Total Asset | 6.3 K | 29.47 B |
| Retained Earnings | (25.59 M) | 9.33 B |
| Working Capital | (7.03 M) | 1.48 B |
| Current Asset | 55 K | 9.34 B |
| Current Liabilities | 7.08 M | 7.9 B |
| Net Asset | 6.3 K |
GeneThera Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as GeneThera . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About GeneThera Buy or Sell Advice
When is the right time to buy or sell GeneThera? Buying financial instruments such as GeneThera Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having GeneThera in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.